Phase 2 trial demonstrates Brukinsa (zanubrutinib) combined with R-CHOP achieves 89.6% objective response rate and 83.3% complete response rate in double-expressor lymphoma patients.

Pharmaceutical companies are increasingly turning to behavioral science principles to overcome barriers in prescribing patterns and drive adoption of new therapies, moving beyond traditional educational approaches.

ReNetX Bio is advancing a treatment to reverse paralysis from spinal cord injuries, showing early signs of neural plasticity in clinical trials.

Roche has agreed to acquire two experimental breast cancer drugs, next-generation CDK inhibitors, from Regor Therapeutics for $850 million upfront.

EDAP TMS has initiated a Phase I/II clinical trial evaluating Focal One robotic HIFU for benign prostatic hyperplasia (BPH) treatment.

Maze Therapeutics has begun a Phase 1 clinical trial for MZE782, a novel oral small molecule targeting SLC6A19, in healthy volunteers.

Real-world studies indicate that weight loss from GLP-1 agonists is less pronounced than reported in clinical trials, with patients achieving only a 3.7% average weight loss after one year.

The FDA granted Priority Review to AstraZeneca's Calquence (acalabrutinib) for untreated mantle cell lymphoma (MCL), expediting its potential approval.

The LUMINOSITY trial evaluated telisotuzumab vedotin (Teliso-V) in patients with c-Met protein–overexpressing, EGFR wild-type, nonsquamous non–small cell lung cancer (NSCLC).

Abivax has initiated its Phase 2b ENHANCE-CD trial, with the first patient enrolled to evaluate obefazimod in Crohn's disease.

TiumBio has dosed the first patient in a Phase 2 clinical trial of TU2218, an oral dual inhibitor targeting TGFR1 and VEGFR2.

ABBV-969, an investigational drug, is under evaluation in a Phase 1 trial for metastatic castration-resistant prostate cancer (mCRPC) treatment.

A phase II trial evaluated fulvestrant with or without enzalutamide in ER+/HER2- breast cancer patients, showing the combination may improve treatment response.

A retrospective study reveals that GLP-1 agonists accelerate preoperative weight loss in obese patients undergoing elective hernia repair.

CRISPR-Cas9 targeting VEGFA delivered via AAV vectors reduces VEGF levels in monkeys, potentially treating choroidal neovascularisation (CNV).

A new blood test can predict treatment response and survival in men newly diagnosed with metastatic hormone-sensitive prostate cancer (mHSPC).

Scholar Rock's apitegromab demonstrated improved motor function in spinal muscular atrophy (SMA) patients in a Phase 3 trial.

The REDUCe2 study investigates long-term abdominal drains (LTADs) for managing ascites in cirrhosis patients, a debilitating condition causing pain and breathlessness.

Rgenta Therapeutics has initiated a Phase 1a/b clinical trial of RGT-61159, an oral small molecule targeting MYB, in patients with advanced adenoid cystic carcinoma (ACC) and colorectal cancer (CRC).

Scholar Rock's apitegromab demonstrated positive pivotal data in patients with spinal muscular atrophy (SMA).